



## Dear MMA and PA Community,

We are excited to inform you that our **HERO** (HElp Reduce Organic Acids) clinical study has begun.

The HERO Study is enrolling at least 12 patients with MMA and PA aged 2 and older at select leading children's hospitals in the United States.



The study is currently open at the University of Minnesota in Minneapolis, MN and Children's Mercy Hospital in Kansas City, MO. More sites will open soon and you can learn more about the study and locations on [Clinicaltrials.gov](https://www.clinicaltrials.gov).

The HERO study will assess HST5040, an oral therapy developed by HemoShear to reduce the toxins that cause harm in MMA and PA patients. HST5040 has the potential to be active throughout the body, including the brain, heart, liver, kidneys and muscles. The drug can be taken conveniently at home as a daily liquid formulation by mouth or through a gastric feeding tube.

## ATTEND WEBINAR



HemoShear is collaborating with OAA and PAF to conduct a webinar, [New Horizons for MMA and PA](#) on Saturday April 17, 2021 from 1 pm - 2:30 pm Eastern.

This webinar will feature a panel of experts to educate families about the current state of treatment and potential future options. The speakers will talk about how the clinical research process works and share information about HST5040 and the design of the HERO Study.

## YOU ARE A HERO!

Making medical progress to improve the quality of life for MMA and PA patients is going to be a collaborative process between industry, clinical researchers and families. We invite you to visit our [website](#) and sign up if you want to receive updates from us.

We are humbled and excited to see if our drug can make a positive difference in patients' lives.

On behalf of the entire HemoShear team, thank you for your interest and support.

Sincerely,

A handwritten signature in black ink, appearing to read "Brian Wamhoff".

Brian Wamhoff, PhD  
*Co-Founder and Head of Innovation*